Unknown

Dataset Information

0

Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosis.


ABSTRACT: Multi- and extensively drug-resistant tuberculosis (M/XDR-TB) has become an increasing threat not only in countries where the TB burden is high but also in affluent regions, due to increased international travel and globalization. Carbapenems are earmarked as potentially active drugs for the treatment of Mycobacterium tuberculosis To better understand the potential of carbapenems for the treatment of M/XDR-TB, the aim of this review was to evaluate the literature on currently available in vitro, in vivo, and clinical data on carbapenems in the treatment of M. tuberculosis and to detect knowledge gaps, in order to target future research. In February 2018, a systematic literature search of PubMed and Web of Science was performed. Overall, the results of the studies identified in this review, which used a variety of carbapenem susceptibility tests on clinical and laboratory strains of M. tuberculosis, are consistent. In vitro, the activity of carbapenems against M. tuberculosis is increased when used in combination with clavulanate, a BLaC inhibitor. However, clavulanate is not commercially available alone, and therefore, it is impossible in practice to prescribe carbapenems in combination with clavulanate at this time. Few in vivo studies have been performed, including one prospective, two observational, and seven retrospective clinical studies to assess the effectiveness, safety, and tolerability of three different carbapenems (imipenem, meropenem, and ertapenem). We found no clear evidence at the present time to select one particular carbapenem among the different candidate compounds to design an effective M/XDR-TB regimen. Therefore, more clinical evidence and dose optimization substantiated by hollow-fiber infection studies are needed to support repurposing carbapenems for the treatment of M/XDR-TB.

SUBMITTER: van Rijn SP 

PROVIDER: S-EPMC6355583 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant <i>Mycobacterium tuberculosis</i>.

van Rijn Sander P SP   Zuur Marlanka A MA   Anthony Richard R   Wilffert Bob B   van Altena Richard R   Akkerman Onno W OW   de Lange Wiel C M WCM   van der Werf Tjip S TS   Kosterink Jos G W JGW   Alffenaar Jan-Willem C JC  

Antimicrobial agents and chemotherapy 20190129 2


Multi- and extensively drug-resistant tuberculosis (M/XDR-TB) has become an increasing threat not only in countries where the TB burden is high but also in affluent regions, due to increased international travel and globalization. Carbapenems are earmarked as potentially active drugs for the treatment of <i>Mycobacterium tuberculosis</i> To better understand the potential of carbapenems for the treatment of M/XDR-TB, the aim of this review was to evaluate the literature on currently available <i  ...[more]

Similar Datasets

| S-EPMC4813232 | biostudies-literature
| S-EPMC2679150 | biostudies-other
| S-EPMC2673722 | biostudies-literature
2009-04-04 | GSE15540 | GEO
2009-04-04 | E-GEOD-15540 | biostudies-arrayexpress
| S-EPMC3957771 | biostudies-literature
| S-EPMC4982626 | biostudies-literature
| S-EPMC6441780 | biostudies-literature
| S-EPMC2593274 | biostudies-literature
| S-EPMC7045844 | biostudies-literature